

Journal of Pediatric Hematology and Oncology

Pediatric EBV positive Mucocutaneous Ulceration in stomach a rare entity

--Manuscript Draft--

Manuscript Number:	JPHO-21-147R1
Full Title:	Pediatric EBV positive Mucocutaneous Ulceration in stomach a rare entity
Article Type:	Clinical and Laboratory Observations
Section/Category:	Oncology
Keywords:	Epstein Barr Virus, Epstein Barr Virus positive mucocutaneous ulceration, Brentuximab Vedotin
Corresponding Author:	MEHMET ALAKAYA Mersin University Faculty of Medicine Mersin, TURKEY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Mersin University Faculty of Medicine
Corresponding Author's Secondary Institution:	
First Author:	MEHMET ALAKAYA
First Author Secondary Information:	
Order of Authors:	MEHMET ALAKAYA Begumhan Demir GUNDOGAN Ali Ertug ARSLANKOYLU Yasemin Yuyucu KARABULUT Nalan AKYUREK Asuman Nur KARHAN Yusuf USTA Elvan Caglar CITAK
Order of Authors Secondary Information:	
Manuscript Region of Origin:	TURKEY
Abstract:	Epstein Barr Virus related lymphoproliferative diseases may occur in immunocompromised patients or patients with a history of drug use causing immunodeficiency. Epstein Barr Virus positive mucocutaneous ulceration in the new classification of lymphoproliferative diseases in 2016 is very rare in children. Involvement occurs in the skin, oral mucosa, and gastrointestinal system. Gastric involvement is very rare in the literature. There is no case of gastric involvement in children. There are no specified modalities in the treatment of Epstein Barr Virus positive mucocutaneous ulceration. We presented our pediatric patient with Ataxia Telangiectasia who presented with abdominal pain and difficulty swallowing and diagnosed with Epstein Barr Virus positive mucocutaneous ulceration in the stomach. We started Brentuximab Vedotin during the treatment process, and complete remission was achieved after 6 cures of treatment. Our patient is the first case of Epstein Barr Virus positive mucocutaneous ulceration in the pediatric case series.

Correction Note

Dear Editor and Reviewer, first of all thank you for evaluating this case report. Your suggestions made me very happy.

I completed the revision of the article in line with the suggestion of the dear Reviewer.

I've explained them one by one below

Yours sincerely

- 1- In the section of Introduction, Kulinski et al. The sentence is added using the reference of their work. Reference number 5

- 2- The sentence "*A possible explanation is that our patient also had AT and therefore was not able to properly control EBV infection.*" was added to the Discussion section.

Reference given. Number 5

- 3- "*Our case in a small child with AT is the first case of EBV MCU detected in the stomach in a pediatric series.*" The sentence was added.

- 4- All wrong words have been corrected. Changed to Epstein.

- 5- Reference number 5 added. Other reference numbers have been changed due to this change.

Pediatric EBV Positive Mucocutaneous Ulceration in Stomach a Rare Entity

Mehmet Alakaya, MD,* Begumhan Gundogan, MD,† Ali Ertuğ Arslanköylü, MD,* Yasemin Yuyucu Karabulut, MD,‡ Nalan Akyurek, MD,§ Asuman Nur Karhan, MD,¶ Yusuf Usta, MD,¶ and Elvan Caglar Citak, MD,†

*Mersin University Faculty of Medicine Department of Pediatric Intensive Care Unit

†Mersin University Faculty of Medicine Department of Pediatric Oncology

‡Mersin University Faculty of Medicine Department of Pathology

§Gazi University Faculty of Medicine Department of Pathology

¶Mersin University Faculty of Medicine Department of Pediatric Gastroenterology

Correspondence to: MEHMET ALAKAYA, MD

Asst. Professor of Pediatric Intensive Care Unit, Mersin University Faculty of Medicine

Department of Pediatric Intensive Care Unit, Mersin, TURKEY

e-mail address: drmehmetalakaya@mersin.edu.tr

Telephone Number: 0 505 938 4578

Short running title: EBV Positive Mucocutaneous Ulceration

Key Words: Epstein Barr Virus, Epstein Barr Virus positive mucocutaneous ulceration,

Brentuximab Vedotin

The authors declare no conflict of interest

No financial resources

Abstract

1
2 Epstein Barr Virus related lymphoproliferative diseases may occur in immunocompromised
3
4 patients or patients with a history of drug use causing immunodeficiency. Epstein Barr Virus
5
6 positive mucocutaneous ulceration in the new classification of lymphoproliferative diseases in
7
8 2016 is very rare in children. Involvement occurs in the skin, oral mucosa, and gastrointestinal
9
10 system. Gastric involvement is very rare in the literature. There is no case of gastric
11
12 involvement in children. There are no specified modalities in the treatment of Epstein Barr
13
14 Virus positive mucocutaneous ulceration. We presented our pediatric patient with Ataxia
15
16 Telangiectasia who presented with abdominal pain and difficulty swallowing and diagnosed
17
18 with Epstein Barr Virus positive mucocutaneous ulceration in the stomach. We started
19
20 Brentuximab Vedotin during the treatment process, and complete remission was achieved
21
22 after 6 cures of treatment. Our patient is the first case of Epstein Barr Virus positive
23
24 mucocutaneous ulceration in the pediatric case series.
25
26
27
28
29
30

Introduction

31
32 Epstein Barr virus (EBV), also known as human herpesvirus 4 is a linear double-
33
34 stranded DNA virus. It spreads through the oropharyngeal tract and can also be found in
35
36 genital secretions. EBV more often infects B-cells and epithelial cells. It enters B-cells over
37
38 CD21 and to epithelial cells that do not contain CD21 over the host's B1 integrins. (1)
39
40 Asymptomatic primary lytic infection period begins in pursuit of the entry of EBV into the
41
42 cell. It passes on to the latent period by forming a circular nucleic episome within the infected
43
44 cell. (2) EBV-infected B-cells remain latent in lymphoid follicles for a lifetime. (3) Cells that
45
46 have not entered the latent period are controlled by memory B-cell with CD4 lymphocytes.
47
48 During conversion into plasma lymphocyte, EBV episome is made linear, and the lytic period
49
50 begins, and new EBV virions are formed. This control is provided by CD8 lymphocytes and
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Natural Killer cells in immunocompetent individuals. In immunocompromised individuals,
2 this lytic cycle cannot be achieved; EBV-related lymphoproliferative diseases occur. Most of
3
4 the EBV-associated lymphoproliferative diseases are classified under the category of mature
5
6 B-cell neoplasms. After the revision in 2016, the world health organization has defined a new
7
8 Lymphoproliferative disease group named EBV positive mucocutaneous ulceration
9
10 (EBVMCU) in the lymphoid neoplasm classification. (4)
11
12
13

14 Ataxia Telangiectasia (AT) is an immunodeficiency situated in the DNA repair defect
15
16 group and seen as a result of a mutation in the ATM gene. ATM protein encoded by the ATM
17
18 gene assists cell division and DNA repair. ATM mutations cause the ATM protein to be
19
20 reduced or not fully produced such that ultimately, cells cannot repair DNA strand breaks and
21
22 cancerous changes occur over time. AT patients display a pattern of anti-EBV antibodies
23
24 suggestive of poorly controlled EBV replication. (5) The severe course of EBV-related
25
26 infections in patients with AT can be explained by this situation.
27
28
29
30

31 EBVMCU is more often seen in immunocompromised individuals. It is extremely rare
32
33 in pediatric patients. When examining the places of involvement, it is most common in the
34
35 oral mucosa and skin. Although the gastrointestinal tract is the third most common, gastric
36
37 involvement was identified in only 1 adult patient in the literature. In line with our
38
39 knowledge, our patient is the second but the first pediatric patient in terms of EBVMCU with
40
41 gastric involvement in this respect. There may be different approaches in EBVMCU
42
43 treatment. This conservative follow-up, reducing the drug dose if the patient is receiving
44
45 immunosuppressant therapy, immune-mediated drugs effective on EBV in chemotherapy, and
46
47 new treatment strategies.
48
49
50
51
52

53 Here, we would like to present an 11-year-old boy patient diagnosed with EBVMCU
54
55 in the stomach followed up due to AT, and who was started on Brentixumab Vedotin (BV)
56
57 treatment, successfully treated and still in remission.
58
59
60
61

Case

1
2 Upon detecting telangiectasia in the eyes and oculomotor apraxia on physical
3
4 examination in the center where he applied due to difficulty in walking, frequent falls, and
5
6 speech disorder he encountered when he was 3.5 years old, the genetic examination was
7
8 performed with the pre-diagnosis of ataxia-telangiectasia. The diagnosis was confirmed upon
9
10 detecting NM_000051.3 pY 2036 homozygous mutation in the ATM (11q22) gene. The
11
12 patient, who was followed up in the immunology department, was started on human
13
14 immunoglobulin treatment every 3 weeks. In the physical examination performed due to
15
16 swelling in the right neck six months before his last hospitalization, painless LAP of 2x1 cm
17
18 in size was detected, and USG revealed lymphadenopathy in the right anterior cervical chain,
19
20 the largest of which was 25 mm in the left anterior cervical, and 12 mm in size ovoid. Oral
21
22 antibiotic treatment was started in the patient, and lymph nodes were determined to be a
23
24 regression in size with treatment.
25
26
27
28
29
30

31 At age eleven, patient hospitalized due to abdominal pain and difficulty swallowing.
32
33 An upper gastrointestinal (GI) endoscopy was performed and a large ulcerous lesion with
34
35 fibrinous base extending to both antrum and corpus of the stomach was observed. Smaller
36
37 ulcerative lesions were also observed around the major lesion. Gastric mucosa adjacent to
38
39 lesion was edematous and fragile. Biopsy taken from this area. (Figure 1) Lower
40
41 gastrointestinal endoscopy was normal. The patient, who had respiratory failure and pleural
42
43 effusion and developed septic shock, was taken to the intensive care unit and started to be
44
45 followed up. Empirical antibiotherapy was started for the patient.
46
47
48
49
50

51 Physical examination in the pediatric intensive care unit, the patient was conscious,
52
53 somnolence, and body temperature were high (38.7 ° C). Blood pressure was appropriate for
54
55 his age (110/70 mmHg) after arterial fluid resuscitation. He was tachypneic (32/min),
56
57 dyspneic, his saturation was 84 in the presence of oxygen, and left lung lower zone ventilation
58
59
60
61
62
63
64
65

1 was decreased, and he had fine rales. There were lymphadenopathies on the right and left
2 cervical, the largest of which was 1.5 cm in size. Abdominal and genitourinary system
3
4 examinations were normal. Upon developing acidosis and carbon dioxide retention (Ph: 7.20,
5
6 CO₂: 74 mmHg) in the blood gas taken, the patient was intubated and connected to a
7
8 mechanical ventilator. Hemoglobin (11.7 g/dl) was normal, leukocytosis (22730 / μ L), and
9
10 thrombocytosis (730000/ μ L) were present in laboratory data. Although kidney functions and
11
12 liver function tests were normal, the C-reactive protein was determined high (105.9 g/L).
13
14 There was no reproduction in peripheral and central catheter blood cultures. Upon aspergillus
15
16 growth in the pleural fluid culture of the patient who underwent thoracentesis, antifungal
17
18 therapy was added to the treatment he was receiving.
19
20
21
22
23

24 Atypical CD 30 positive cells were found in the endoscopic biopsy of the patient. It
25
26 was evaluated as primary gastric Hodgkin Lymphoma. Since the incidence of primary gastric
27
28 lymphoma is very low, due to diagnostic suspicion, conducted a biopsy on the lymph node
29
30 from the neck area with PET involvement. The biopsy was evaluated as necrosis and scattered
31
32 histiocytes, and reactive lymphadenitis and a biopsy on the patient again. It was not detected
33
34 the difference in appearance on endoscopy. Upon detecting polymorphic, large atypical cells
35
36 CD 30 (+), CD 20 (+), EBER positive cells in the second biopsy taken, the patient was
37
38 diagnosed with EBVMCU. (Figure 2)
39
40
41
42

43 EBV PCR was detected as positive, and EBV DNA was detected as 4890 copies/ml.
44
45 Due to the immunohistochemically CD30, positive cells were more prominent, BV (Anti CD-
46
47 30) treatment was started at 1.8mg/kg/dose. It was observed that the lesion completely
48
49 regressed in the endoscopy performed after a total of 6 cures of treatment and there was no
50
51 finding in favor of EBVMCU in the biopsy taken. (Figure 3) After the end of treatment's 2
52
53 month the control upper GI endoscopy showed a complete recovery. (Figure 4) The patient is
54
55 still followed-up in remission.
56
57
58
59
60
61
62
63
64
65

DISCUSSION

1
2 EBVMCU was identified after the classification in 2016. (4) It is in the group of
3
4 lymphoproliferative diseases. The first comprehensive study describing this
5
6 lymphoproliferative disease was published by Dojcinov in 2010, and the study included 26
7
8 patients with advanced age-related immunosuppression or drug-induced immunosuppression.
9
10 These patients were self-limiting patients with mucosal or cutaneous ulcers, commonly
11
12 involving the oropharynx, gastrointestinal tract, or skin. (6) EBVMCU is more often seen in
13
14 immunocompromised patients and patients with a history of drug use causing
15
16 immunodeficiency. While Dojcinov et al., in their series, determined the median age of the
17
18 patients in immunosuppressive drug users (iatrogenic) to be 69 years, this median was 80
19
20 years in patients without a history of drug use. It was observed that these patients used
21
22 Methotrexate, Azathioprine, and Cyclosporine A as immunosuppressive agents. (6) Although
23
24 our patient did not use immunosuppressant drugs, he had AT disease that caused
25
26 immunodeficiency. Except for immunoglobulin support, he did not have regular use of
27
28 medication. Accordingly, detailed patient history is very important in patients diagnosed with
29
30 EBVMCU. The patient's underlying disease and drug use should be investigated in detail.
31
32
33
34
35
36
37
38

39 EBVMCU usually presents with a solitary lesion. 17% of the cases in the literature are
40
41 multifocal. Generally, lesions occur on the skin (29%), oral mucosa (52%) or gastrointestinal
42
43 tract (19% - 40% colon, 30% esophagus, 20% rectum and 10% terminal ileum). (7) Although
44
45 it is quite rare in the stomach, it was first shown by EBVMCU Gabsi et al. in a 62-year-old
46
47 male in the stomach, and to our knowledge, no other case of gastric involvement was
48
49 reported. (8) The youngest case with EBVMCU is a patient with 5-month skin involvement in
50
51 the literature. (9) Still, in another study report, a 16-year-old male patient was diagnosed with
52
53 CHARGE syndrome (coloboma, heart defect, atresia of the nasal choanae, retardation of
54
55 growth, genital and ear abnormalities, and deafness) and EBVMCU with nasopharyngeal
56
57
58
59
60
61
62
63
64
65

1 mucosal involvement. (10) In line with our knowledge, our patient is important because it is
2 the first case of EBVMCU in the stomach in children. A possible explanation is that our
3
4 patient also had AT and therefore was not able to properly control EBV infection. (5)
5
6

7 EBVMCU are polymorph infiltrates that may histopathologically contain histiocytes,
8 eosinophils, plasma cells, large pleomorphic immunoblasts similar to Hodgkin reed stenberg
9 (HRS) cells, numerous medium-sized T cells, apoptotic bodies, as well as well-defined ulcers
10 that may include vascular invasions and necrosis. Large pleomorphic blast cells and HRS-like
11 cells express CD20, CD30, CD15, PAX5, OCT2, MUM1, BOB1, EBER, CD45. In 33% of
12 cases, a decrease or absence of CD20 expression is observed. These large atypical cells are
13 positive for EBV's latent membrane protein-1 (LMP-1). (11-12) In consequence of gastric
14 endoscopic biopsy performed before the treatment of our patient, polymorphic, lymphocyte-
15 containing, histiocytes, Hodgkin-like cells, and immunoblasts were present. The diagnosis
16 was made by detecting CD20, CD30, and EBER positivity in atypical large cells. (Figure
17 2A,2A1,2A2,2A3)
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Although EBVMCU does not have treatment instructions and guidelines, the treatment
34 regimen, which is generally common in adult patients, is conservative. In the use of
35 immunosuppressant drugs, discontinuation or dose reduction is recommended. Studies
36 conducted were determined that complete remission is achieved in the range of 2-12 weeks in
37 2/3 of EBVMCU cases using immunosuppressive drugs. However, the median duration is 4
38 weeks with only drug dose reduction. Rarely, progression and relapse were observed. (7-13)
39 However, some studies have shown that 36% of patients diagnosed with EBVMCU are
40 administered aggressive treatment, although it is a self-limiting diagnosis and that Rituximab
41 or drugs can increase immunological control EBV are used in these treatments. There are also
42 cases where chemotherapy protocols are applied. (14-15-16) Nevertheless, the factors that
43 contribute to a treatment strategy's decision to be applied and the prognosis prediction have
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 not been clarified yet. We preferred our patient to be hospitalized in the intensive care unit
2 due to the underlying immune deficiency and anti CD30 monoclonal antibody BV, one of the
3 new targeted treatment regimens, because of the patient's CD30 positivity. BV targets CD30
4 overproduced from Hodgkin and Reed Sternberg cells and large cell lymphoma malignant
5 cells. This drug is highly effective in a wide range of CD30 positive lymphomas such as
6 classical Hodgkin lymphoma, anaplastic large cell lymphoma, T cell lymphoma, and diffuse
7 large B cell lymphoma. BV binds to CD 30 on the cell surface. Vedotin is transported to the
8 nucleus cells, joining the cell cycle, disrupting the cycle and causing apoptosis. Pediatric
9 experience confirms adult patient data. In the study of Locatelli et al., it has been shown that
10 single-agent brentuximab vedotin treatment is effective in pediatric patients with poor
11 prognosis Hodgkin lymphoma and systemic anaplastic large cell lymphoma. (17-18-19-20)
12 There are also studies applying BV in EBVMCU treatment. Thomas Pincez et al. in their
13 study have demonstrated the effectiveness of BV therapy in a patient who was diagnosed with
14 EBV positive Burkitt Lymphoma at the age of 11 and who was diagnosed with primary colon
15 originated EBVMCU as a result of examinations performed for persistent fever, diarrhea, and
16 weight loss during follow-up. It was found that the disease regressed after the first week, and
17 the EBVMCU did not recur after the treatment. (21) Still, in the same study, BV was used in a
18 case diagnosed with AT in childhood. This 16 years old patient was applied with dysphagia,
19 anorexia, and a severe eating disorder. In his/her examination, severe palatine ulcer and
20 cervical lymphadenopathy were detected. In his/her biopsy, according to the
21 lymphoproliferative patient classification, it was diagnosed as monomorphic non-germinal
22 center B-cell. Complete response was received from 3 months of BV treatment. (21)

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
There is no data in the literature regarding the treatment of primary gastric-derived
EBVMCU. BV treatment was administered to our patient at 1.8 mg/kg/dose every 3 weeks.

1 Complete remission was achieved after a total of 6 cures of treatment. The patient was sent to
2 the palliative care center with oxygen support.
3

4 **Conclusion**

5
6
7 Consequently, mucocutaneous ulcers should be kept in mind when immunocompromised
8
9 children present with gastrointestinal symptoms. Solely after our knowledge increases, the
10
11 most appropriate treatment will be determined in these patients according to the underlying
12
13 disease. Although EBVMCU is very rare in childhood, weight loss in immunosuppressive
14
15 patients should not be overlooked in children with nutritional problems. Our case in a small
16
17 child with AT is the first case of EBVMCU detected in the stomach in a pediatric series. We
18
19 think that appropriate treatment modalities will be determined by the increase of our
20
21
22
23
24 knowledge about this disease.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The authors declare no conflict of interest

No financial resources

References

- 1- Wang X, Hutt-Fletcher LM. Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. *J Virol* 1998; 72:158-163
- 2- Odumade OA, Hogquist KA, Balfour HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections. *Clin Microbiol Rev* 2011; 24:193-209.
- 3- Tse E, Kwong YL. Epstein Barr viruse associated lymphoproliferative diseases: the virus as a therapeutic target. *Exp Mol Med* 2015; 47: e136-137
- 4- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* 2016; 127:2375-2390
- 5- Kulinski JM, Leonardo SM, Mounce BC et al. Ataxia telangiectasia mutated kinase controls chronic gammaherpesvirus infection. *J Virol*; 2012; 86:12826-12837
- 6- Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer a study of 26 cases associated with various sources of immunosuppression. *Am J Surg Pathol* 2010; 34:405-417
- 7- Roberts TK, Chen X, Liao JJ. Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature. *Exp Hematol Oncol*. 2016; 5:13
- 8- Gabsi A, Zenzri Y, Sahraoui G, et al. Gastric EBV-positive mucocutaneous ulcer: A rare pathological entity. *Clin Case Rep*. 2020; 8: 1130–1133

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 9- Coelho KMPA, Bublitz GS, França PHC, et al. Epstein-Barr Virus-Positive Mucocutaneous Ulcer in a Pediatric Patient-Case Report. *Am J Dermatopathol.* 2020 Apr;42(4): e49-e52
 - 10- Natkunam Y, Goodlad JR, Chadburn A, et al. EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report-Part 1. *Am J Clin Pathol.* 2017; 147: 129–152
 - 11- Gratzinger D, Jaffe ES. Mucocutaneous ulcer: a mimic of EBV+ diffuse large B cell lymphoma in the immunodeficiency setting. *Leuk Lymphoma.* 2016; 57: 1982-1983
 - 12- Wanderlei KC, Quintella DC, Cuzzi T, et al. EBV-positive mucocutaneous ulcers: a presentation of two cases and a brief literature review. *Surgical and Experimental Pathology* (2019) 2:13 <https://doi.org/10.1186/s42047-019-0037-8>
 - 13- Hart M, Thakral B, Yohe S, et al. EBV-positive mucocutaneous ulcer in organ transplant recipients: A localized indolent posttransplant lymphoproliferative disorder. *Am J Surg Pathol.* 2014; 38: 1522–1529
 - 14- Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. *Ann Oncol.* 2009
 - 15- Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. *Blood.* 2007; 110:1123–1131
 - 16- Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. *Hematology Am Soc Hematol Educ Program.* 2005;260–266
 - 17- Eichenauer DA, Plütschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a

phase 2 randomised trial by the German Hodgkin Study Group. *Lancet Oncol.*

2017;18(12):1680-1687

18- Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30- positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet.* 2019; 393: 229-240

19- Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab Vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. *Blood.* 2015;125(9):1394-1402

20- Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. *Lancet Haematol.* 2018;5(10): e450-e461.

21- Pincez T, Bruneau J, Berteloot L, et al. Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies. *Haematologica.* 2020 ;105(9): e461-464

Figure Legends

Figure 1- Large ulcerous lesion in antrum and corpus of the stomach


Figure 2- Endoscopic biopsy results (2A- The infiltrate is polymorphous, containing lymphocytes, histiocytes, immunoblasts, and Hodgkin-like cells. (HE, original magnification x200), Large atypical cells were positive for CD20 (2A1), CD30 (2A2) and EBER (2A3); (original magnification: a-c x200)


Figure 3- The restricted image of the ulcerative lesion with a healed mucosal appearance

Figure 4- Healed gastric mucosa

Figure 1

[Click here to access/download;Figure \(TIF or EPS only; 300 ppi images and 1200 ppi Line-Art\);Figure 1.tif](#)









Figure 4

[Click here to access/download;Figure \(TIF or EPS only; 300 ppi images and 1200 ppi Line-Art\);Figure 4.tif](#)



Pediatric EBV positive Mucocutaneous Ulceration in stomach a rare entity

Abstract

Epstein Barr Virus related lymphoproliferative diseases may occur in immunocompromised patients or patients with a history of drug use causing immunodeficiency. Epstein Barr Virus positive mucocutaneous ulceration in the new classification of lymphoproliferative diseases in 2016 is very rare in children. Involvement occurs in the skin, oral mucosa, and gastrointestinal system. Gastric involvement is very rare in the literature. There is no case of gastric involvement in children. There are no specified modalities in the treatment of Epstein Barr Virus positive mucocutaneous ulceration. We presented our pediatric patient with Ataxia Telangiectasia who presented with abdominal pain and difficulty swallowing and diagnosed with Epstein Barr Virus positive mucocutaneous ulceration in the stomach. We started Brentuximab Vedotin during the treatment process, and complete remission was achieved after 6 cures of treatment. Our patient is the first case of Epstein Barr Virus positive mucocutaneous ulceration in the pediatric case series.

Key Words: Epstein Barr Virus, Epstein Barr Virus positive mucocutaneous ulceration, Brentuximab Vedotin

Introduction

1
2
3 Epstein Barr virus (EBV), also known as human herpesvirus 4 is a linear double-
4 stranded DNA virus. It spreads through the oropharyngeal tract and can also be found in genital
5 secretions. EBV more often infects B-cells and epithelial cells. It enters B-cells over CD21 and
6
7 epithelial cells that do not contain CD21 over the host's B1 integrins. (1) Asymptomatic
8 primary lytic infection period begins in pursuit of the entry of EBV into the cell. It passes on to
9
10 the latent period by forming a circular nucleic episome within the infected cell. (2) EBV-
11
12 infected B-cells remain latent in lymphoid follicles for a lifetime. (3) Cells that have not entered
13
14 the latent period are controlled by memory B-cell with CD4 lymphocytes. During conversion
15
16 into plasma lymphocyte, EBV episome is made linear, and the lytic period begins, and new
17
18 EBV virions are formed. This control is provided by CD8 lymphocytes and Natural Killer cells
19
20 in immunocompetent individuals. In immunocompromised individuals, this lytic cycle cannot
21
22 be achieved; EBV-related lymphoproliferative diseases occur. Most of the EBV-associated
23
24 lymphoproliferative diseases are classified under the category of mature B-cell neoplasms.
25
26 After the revision in 2016, the world health organization has defined a new Lymphoproliferative
27
28 disease group named EBV positive mucocutaneous ulceration (EBVMCU) in the lymphoid
29
30 neoplasm classification. (4)
31
32
33
34
35
36
37
38
39
40
41

42 Ataxia Telangiectasia (AT) is an immunodeficiency situated in the DNA repair defect
43 group and seen as a result of a mutation in the ATM gene. ATM protein encoded by the ATM
44 gene assists cell division and DNA repair. ATM mutations cause the ATM protein to be reduced
45
46 or not fully produced such that ultimately, cells cannot repair DNA strand breaks and cancerous
47
48 changes occur over time. AT patients display a pattern of anti-EBV antibodies suggestive of
49
50 poorly controlled EBV replication. (5) The severe course of EBV-related infections in patients
51
52 with AT can be explained by this situation.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

EBVMCU is more often seen in immunocompromised individuals. It is extremely rare in pediatric patients. When examining the places of involvement, it is most common in the oral mucosa and skin. Although the gastrointestinal tract is the third most common, gastric involvement was identified in only 1 adult patient in the literature. In line with our knowledge, our patient is the second but the first pediatric patient in terms of EBVMCU with gastric involvement in this respect. There may be different approaches in EBVMCU treatment. This conservative follow-up, reducing the drug dose if the patient is receiving immunosuppressant therapy, immune-mediated drugs effective on EBV in chemotherapy, and new treatment strategies.

Here, we would like to present an 11-year-old boy patient diagnosed with EBVMCU in the stomach followed up due to AT, and who was started on Brentixumab Vedotin (BV) treatment, successfully treated and still in remission.

Case

Upon detecting telangiectasia in the eyes and oculomotor apraxia on physical examination in the center where he applied due to difficulty in walking, frequent falls, and speech disorder he encountered when he was 3.5 years old, the genetic examination was performed with the pre-diagnosis of ataxia-telangiectasia. The diagnosis was confirmed upon detecting NM_000051.3 pY 2036 homozygous mutation in the ATM (11q22) gene. The patient, who was followed up in the immunology department, was started on human immunoglobulin treatment every 3 weeks. In the physical examination performed due to swelling in the right neck six months before his last hospitalization, painless LAP of 2x1 cm in size was detected, and USG revealed lymphadenopathy in the right anterior cervical chain, the largest of which was 25 mm in the left anterior cervical, and 12 mm in size ovoid. Oral antibiotic treatment was started in the patient, and lymph nodes were determined to be a regression in size with treatment.

At eleven aged: patient hospitalized due to abdominal pain and difficulty swallowing.

1
2 An upper gastrointestinal (GI) endoscopy was performed and a large ulcerous lesion with
3
4 fibrinous base extending to both antrum and corpus of the stomach was observed. Smaller
5
6 ulcerative lesions were also observed around the major lesion. Gastric mucosa adjacent to lesion
7
8 was oedematous and fragile. Biopsy taken from this area. (Figure 1) Lower gastrointestinal
9
10 endoscopy was normal. The patient, who had respiratory failure and pleural effusion and
11
12 developed septic shock, was taken to the intensive care unit and started to be followed up.
13
14 Empirical antibiotherapy was started for the patient.
15
16
17
18
19

20 Physical examination in the pediatric intensive care unit, the patient was conscious,
21
22 somnolence, and body temperature were high (38.7 ° C). Blood pressure was appropriate for
23
24 his age (110/70 mmHg) after arterial fluid resuscitation. He was tachypneic (32/min), dyspneic,
25
26 his saturation was 84 in the presence of oxygen, and left lung lower zone ventilation was
27
28 decreased, and he had fine rales. There were lymphadenopathies on the right and left cervical,
29
30 the largest of which was 1.5 cm in size. Abdominal and genitourinary system examinations
31
32 were normal. Upon developing acidosis and carbon dioxide retention (Ph: 7.20, CO₂: 74
33
34 mmHg) in the blood gas taken, the patient was intubated and connected to a mechanical
35
36 ventilator. Hemoglobin (11.7 g/dl) was normal, leukocytosis (22730 /μL), and thrombocytosis
37
38 (730000/μL) were present in laboratory data. Although kidney functions and liver function tests
39
40 were normal, the C-reactive protein was determined high (105.9 g/L). There was no
41
42 reproduction in peripheral and central catheter blood cultures. Upon aspergillus growth in the
43
44 pleural fluid culture of the patient who underwent thoracentesis, antifungal therapy was added
45
46 to the treatment he was receiving.
47
48
49
50
51
52
53

54 Atypical CD 30 positive cells were found in the endoscopic biopsy of the patient. It was
55
56 evaluated as primary gastric Hodgkin Lymphoma. Since the incidence of primary gastric
57
58 lymphoma is very low, due to diagnostic suspicion, conducted a biopsy on the lymph node from
59
60
61
62
63
64
65

1 the neck area with PET involvement. The biopsy was evaluated as necrosis and scattered
2 histiocytes, and reactive lymphadenitis and a biopsy on the patient again. It was not detected
3
4 the difference in appearance on endoscopy. Upon detecting polymorphic, large atypical cells
5
6 CD 30 (+), CD 20 (+), EBER positive cells in the second biopsy taken, the patient was
7
8 diagnosed with EBVMCU. (Figure 2)
9
10

11
12 EBV PCR was detected as positive, and EBV DNA was detected as 4890 copies/ml.
13
14 Due to the immunohistochemically CD30, positive cells were more prominent, BV (Anti CD-
15
16 30) treatment was started at 1.8mg/kg/dose. It was observed that the lesion completely regressed
17
18 in the endoscopy performed after a total of 6 cures of treatment and there was no finding in
19
20 favor of EBVMCU in the biopsy taken. (Figure 3) After the end of treatment's 2 month the
21
22 control upper GI endoscopy showed a complete recovery. (Figure 4) The patient is still
23
24 followed-up in remission.
25
26
27
28
29

30 **DISCUSSION**

31
32
33 EBVMCU was identified after the classification in 2016. (4) It is in the group of
34
35 lymphoproliferative diseases. The first comprehensive study describing this
36
37 lymphoproliferative disease was published by Dojcinov in 2010, and the study included 26
38
39 patients with advanced age-related immunosuppression or drug-induced immunosuppression.
40
41 These patients were self-limiting patients with mucosal or cutaneous ulcers, commonly
42
43 involving the oropharynx, gastrointestinal tract, or skin. (6) EBVMCU is more often seen in
44
45 immunocompromised patients and patients with a history of drug use causing
46
47 immunodeficiency. While Dojcinov et al., in their series, determined the median age of the
48
49 patients in immunosuppressive drug users (iatrogenic) to be 69 years, this median was 80 years
50
51 in patients without a history of drug use. It was observed that these patients used Methotrexate,
52
53 Azathioprine, and Cyclosporine A as immunosuppressive agents. (6) Although our patient did
54
55 not use immunosuppressant drugs, he had AT disease that caused immunodeficiency. Except
56
57
58
59
60
61
62
63
64
65

1 for immunoglobulin support, he did not have regular use of medication. Accordingly, detailed
2 patient history is very important in patients diagnosed with EBVMCU. The patient's underlying
3 disease and drug use should be investigated in detail.
4
5

6
7 EBVMCU usually presents with a solitary lesion. 17% of the cases in the literature are
8 multifocal. Generally, lesions occur on the skin (29%), oral mucosa (52%) or gastrointestinal
9 tract (19% - 40% colon, 30% esophagus, 20% rectum and 10% terminal ileum). (7) Although
10 it is quite rare in the stomach, it was first shown by EBVMCU Gabsi et al. in a 62-year-old
11 male in the stomach, and to our knowledge, no other case of gastric involvement was reported.
12 (8) The youngest case with EBVMCU is a patient with 5-month skin involvement in the
13 literature. (9) Still, in another study report, a 16-year-old male patient was diagnosed with
14 CHARGE syndrome (coloboma, heart defect, atresia of the nasal choanae, retardation of
15 growth, genital and ear abnormalities, and deafness) and EBVMCU with nasopharyngeal
16 mucosal involvement. (10) In line with our knowledge, our patient is important because it is the
17 first case of EBVMCU in the stomach in children. A possible explanation is that our patient
18 also had AT and therefore was not able to properly control EBV infection. (5)
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 EBVMCU are polymorph infiltrates that may histopathologically contain histiocytes,
38 eosinophils, plasma cells, large pleomorphic immunoblasts similar to Hodgkin reed stenberg
39 (HRS) cells, numerous medium-sized T cells, apoptotic bodies, as well as well-defined ulcers
40 that may include vascular invasions and necrosis. Large pleomorphic blast cells and HRS-like
41 cells express CD20, CD30, CD15, PAX5, OCT2, MUM1, BOB1, EBER, CD45. In 33% of
42 cases, a decrease or absence of CD20 expression is observed. These large atypical cells are
43 positive for EBV's latent membrane protein-1 (LMP-1). (11-12) In consequence of gastric
44 endoscopic biopsy performed before the treatment of our patient, polymorphic, lymphocyte-
45 containing, histiocytes, Hodgkin-like cells, and immunoblasts were present. The diagnosis was
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

made by detecting CD20, CD30, and EBER positivity in atypical large cells. (Figure 2A,2A1,2A2,2A3)

Although EBVMCU does not have treatment instructions and guidelines, the treatment regimen, which is generally common in adult patients, is conservative. In the use of immunosuppressant drugs, discontinuation or dose reduction is recommended. Studies conducted were determined that complete remission is achieved in the range of 2-12 weeks in 2/3 of EBVMCU cases using immunosuppressive drugs. However, the median duration is 4 weeks with only drug dose reduction. Rarely, progression and relapse were observed. (7-13) However, some studies have shown that 36% of patients diagnosed with EBVMCU are administered aggressive treatment, although it is a self-limiting diagnosis and that Rituximab or drugs can increase immunological control EBV are used in these treatments. There are also cases where chemotherapy protocols are applied. (14-15-16) Nevertheless, the factors that contribute to a treatment strategy's decision to be applied and the prognosis prediction have not been clarified yet. We preferred our patient to be hospitalized in the intensive care unit due to the underlying immune deficiency and anti CD30 monoclonal antibody BV, one of the new targeted treatment regimens, because of the patient's CD30 positivity. BV targets CD30 overproduced from Hodgkin and Reed Sternberg cells and large cell lymphoma malignant cells. This drug is highly effective in a wide range of CD30 positive lymphomas such as classical Hodgkin lymphoma, anaplastic large cell lymphoma, T cell lymphoma, and diffuse large B cell lymphoma. BV binds to CD 30 on the cell surface. Vedotin is transported to the nucleus cells, joining the cell cycle, disrupting the cycle and causing apoptosis. Pediatric experience confirms adult patient data. In the study of Locatelli et al., it has been shown that single-agent brentuximab vedotin treatment is effective in pediatric patients with poor prognosis Hodgkin lymphoma and systemic anaplastic large cell lymphoma. (17-18-19-20) There are also studies applying BV in EBVMCU treatment. Thomas Pincez et al. in their study have demonstrated

1 the effectiveness of BV therapy in a patient who was diagnosed with EBV positive Burkitt
2 Lymphoma at the age of 11 and who was diagnosed with primary colon originated EBVMCU
3
4 as a result of examinations performed for persistent fever, diarrhea, and weight loss during
5
6 follow-up. It was found that the disease regressed after the first week, and the EBVMCU did
7
8 not recur after the treatment. (21) Still, in the same study, BV was used in a case diagnosed
9
10 with AT in childhood. This 16 years old patient was applied with dysphagia, anorexia, and a
11
12 severe eating disorder. In his/her examination, severe palatine ulcer and cervical
13
14 lymphadenopathy were detected. In his/her biopsy, according to the lymphoproliferative patient
15
16 classification, it was diagnosed as monomorphic non-germinal center B-cell. Complete
17
18 response was received from 3 months of BV treatment. (21)
19
20
21
22
23
24

25 There is no data in the literature regarding the treatment of primary gastric-derived
26
27 EBVMCU. BV treatment was administered to our patient at 1.8 mg/kg/dose every 3 weeks.
28
29 Complete remission was achieved after a total of 6 cures of treatment. The patient was sent to
30
31 the palliative care center with oxygen support.
32
33
34

35 **Conclusion**

36
37
38 Consequently, mucocutaneous ulcers should be kept in mind when immunocompromised
39
40 children present with gastrointestinal symptoms. Solely after our knowledge increases, the most
41
42 appropriate treatment will be determined in these patients according to the underlying disease.
43
44 Although EBVMCU is very rare in childhood, weight loss in immunosuppressive patients
45
46 should not be overlooked in children with nutritional problems. **Our case in a small child with**
47
48 **AT is the first case of EBVMCU detected in the stomach in a pediatric series.** We think that
49
50 appropriate treatment modalities will be determined by the increase of our knowledge about
51
52 this disease.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 The authors declare no conflict of interest

4
5
6
7
8
9 No financial resources

10 **References**

- 11 1- Wang X, Hutt-Fletcher LM. Epstein-Barr virus lacking glycoprotein gp42 can bind to
12 B cells but is not able to infect. *J Virol* 1998; 72:158-163
13
14
15
16
17 2- Odumade OA, Hogquist KA, Balfour HH. Progress and problems in understanding
18 and managing primary Epstein-Barr virus infections. *Clin Microbiol Rev* 2011;
19 24:193-209.
20
21
22
23
24
25 3- Tse E, Kwong YL. Epstein Barr viruse associated lymphoproliferative diseases: the
26 virus as a therapeutic target. *Exp Mol Med* 2015; 47: e136-137
27
28
29
30
31 4- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health
32 Organization classification of lymphoid neoplasms. *Blood* 2016; 127:2375-2390
33
34
35
36 5- Kulinski JM, Leonardo SM, Mounce BC et al. Ataxia telangiectasia mutated kinase
37 controls chronic gammaherpesvirus infection. *J Virol*; 2012; 86:12826-12837
38
39
40
41
42 6- Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer a
43 study of 26 cases associated with various sources of immunosuppression. *Am J Surg*
44 *Pathol* 2010; 34:405-417
45
46
47
48
49
50 7- Roberts TK, Chen X, Liao JJ. Diagnostic and therapeutic challenges of EBV-positive
51 mucocutaneous ulcer: a case report and systematic review of the literature. *Exp*
52 *Hematol Oncol.* 2016; 5:13
53
54
55
56
57
58 8- Gabsi A, Zenzri Y, Sahraoui G, et al. Gastric EBV-positive mucocutaneous ulcer: A
59 rare pathological entity. *Clin Case Rep.* 2020; 8: 1130–1133
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 9- Coelho KMPA, Bublitz GS, França PHC, et al. Epstein-Barr Virus-Positive Mucocutaneous Ulcer in a Pediatric Patient-Case Report. *Am J Dermatopathol.* 2020 Apr;42(4): e49-e52
 - 10- Natkunam Y, Goodlad JR, Chadburn A, et al. EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report-Part 1. *Am J Clin Pathol.* 2017; 147: 129–152
 - 11- Gratzinger D, Jaffe ES. Mucocutaneous ulcer: a mimic of EBV+ diffuse large B cell lymphoma in the immunodeficiency setting. *Leuk Lymphoma.* 2016; 57: 1982-1983
 - 12- Wanderlei KC, Quintella DC, Cuzzi T, et al. EBV-positive mucocutaneous ulcers: a presentation of two cases and a brief literature review. *Surgical and Experimental Pathology* (2019) 2:13 <https://doi.org/10.1186/s42047-019-0037-8>
 - 13- Hart M, Thakral B, Yohe S, et al. EBV-positive mucocutaneous ulcer in organ transplant recipients: A localized indolent posttransplant lymphoproliferative disorder. *Am J Surg Pathol.* 2014; 38: 1522–1529
 - 14- Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. *Ann Oncol.* 2009
 - 15- Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. *Blood.* 2007; 110:1123–1131
 - 16- Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. *Hematology Am Soc Hematol Educ Program.* 2005;260–266

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
- 17- Eichenauer DA, Plütschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. *Lancet Oncol.* 2017;18(12):1680-1687
- 18- Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30- positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet.* 2019; 393: 229-240
- 19- Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab Vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. *Blood.* 2015;125(9):1394-1402
- 20- Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. *Lancet Haematol.* 2018;5(10): e450-e461.
- 21- Pincez T, Bruneau J, Berteloot L, et al. Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies. *Haematologica.* 2020 ;105(9): e461-464

44
45
46
47
48
49

Figure Legends

50
51
52
53
54
55

Figure 1- Large ulcerous lesion in antrum and corpus of the stomach

56
57
58
59
60
61
62
63
64
65

Figure 2- Endoscopic biopsy results (2A- The infiltrate is polymorphous, containing lymphocytes, histiocytes, immunoblasts, and Hodgkin-like cells. (HE, original magnification x200), Large atypical cells were positive for CD20 (2A1), CD30 (2A2) and EBER (2A3); (original magnification: a-c x200)

Figure 3- The restricted image of the ulcerative lesion with a healed mucosal appearance

Figure 4- Healed gastric mucosa